ADGM · Adagio Medical Holdings, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As of the report date, we do not believe our existing cash and cash equivalents are sufficient to fund our operating and capital expenditure requirements for at least 12 months from the date of issuance of the audited consolidated financial statements included in this Report. Based on our current research and development plans, we expect to have sufficient resources to fund our planned operations into the fourth quarter of 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than expected. No assurance can be given as to whether additional needed financing will be available on terms acceptable to us, if at all. If sufficient funds on acceptable terms are not available when needed, we may be required to suspend or forego certain planned activities. Failure to manage discretionary spending or raise additional financing, as needed, could adversely impact our ability to achieve our intended business objectives and may have an adverse effect on our results of operations and future prospects. These factors raise substantial doubt about our ability to continue as a going concern for the twelve-month period from the date of this filing with the SEC.”View the 10-Q filed Aug 11, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADGM
this stock
Adagio Medical Holdings, Inc.
|
$2.38M | -88.9% | — | — | 5.8% |
|
ABT
Abbott Laboratories
|
$178.00B | -19.8% | +5.7% | 33.1 | 0.8% |
|
MDT
Medtronic plc
|
$119.00B | -3.2% | +8.4% | 22.9 | 3.1% |
|
SYK
Stryker Corp
|
$116.40B | -15.3% | +11.2% | 31.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$64.51B | -53.3% | +12.5% | 18.0 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 13, 2026
- This year
- 22
Adagio Medical Holdings, Inc. will ask stockholders on October 23, 2026 to approve a reverse stock split from 1-for-10 to 1-for-500, with the Board determining the ratio as a means of regaining Nasdaq minimum bid price compliance.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADGM | +29.6% | -49.4% | -87.2% | -24.6% | -88.9% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | +29.1% | -50.1% | -94.8% | -26.0% | -102.3% |